Cilofexor

• Description :

  Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research[1][2].

• Product Name Alternative :

  GS-9674

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H312, H332

• Target :

  Autophagy; FXR

• Type :

  Reference compound

• Related Pathways :

  Autophagy; Metabolic Enzyme/Protease

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/Cilofexor.html

• Purity :

  99.82

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  ClC1=C(C2(CN(C3=CC(C(O)=O)=CC=N3)C2)O)C=CC(OCC4=C(C5CC5)ON=C4C(C(Cl)=CC=C6)=C6Cl)=C1

• Molecular Formula :

  C28H22Cl3N3O5

• Molecular Weight :

  586.85

• Precautions :

  H302, H312, H332

• References & Citations :

  [1]Trauner M, et al. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70 (3) :788-801.|[2]Patel K, et al. Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 Mar 1.|[3]P. Schwab, et al. The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH. April 2018, Volume 68, Supplement 1, Pages S471-S472.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 3

• CAS Number :

  [1418274-28-8]